a a a

New approach shows results for Alzheimer's disease

News from the frontier

By Elizabeth Norton Lasley
February 01, 2008

A medication used in treating rheumatoid arthritis has shown dramatic benefits for patients with Alzheimer’s disease, improving memory and cognitive problems within minutes of the start of treatment.

In a 2006 pilot study, 15 patients with Alzheimer’s disease received etanercept (known by the trade name Enbrel) weekly for six  months, using a new method of injection directly overlying the spine. The patients responded quickly and, more than three years later, some are still showing improved memory and cognitive functioning. But that study was not set up for immediate assessment or for follow-up testing more often than once a month, according to study author Edward Tobinick of the University of California, Los Angeles.

In a new case report, published online Jan. 10 in the Journal of Neuroinflammation, Tobinick and Hyman Gross, at the University of
Southern California, worked with an 81-year-old with moderate to severe dementia. The researchers conducted standardized cognitive testing before and after this “perispinal” injection of etanercept.

Ten minutes after the initial dose, he was calmer and less frustrated, correctly stating his location and coming close on what year it was—neither of which he could do before treatment. Two hours after treatment he displayed dramatically improved verbal and memory skills. After six weeks of treatment, the patient continued to show persistent improvement.

Tobinick says that this patient and the participants in the pilot study are functioning better in the real world, not just giving better answers on tests: “They’re more cheerful, relaxed, more ready to join in conversation.”

Etanercept targets a protein called tumor necrosis factor–alpha, produced by white blood cells and, in the brain, by support cells called glia. Recent research suggests that high levels of TNF–alpha disrupt synaptic communication among neurons, setting the stage for the betterknown signs of Alzheimer’s disease, such as buildup of the beta-amyloid protein. The authors note that because one glial cell may make contact with more than 100,000 synapses, correcting a problem at this level may have rapid cognitive and behavioral effects.

Comments

Enbrel

Felicia McColl

5/21/2008 9:11:02 AM

I have now been bringing my Mom to Dr. Tobinick for 11 weeks. She has improved greatly from how she was before we started the injections. I do believe she has leveled off, and stabilized. The exciting part is just that...stabilized! She was spiraling downhill, and I remember thinking she would be an invalid and someone I had to feed within 2 months. Well, it's been almost 3 months and she is walking and eating just fine. She has improved enough that she can enjoy life again, albeit a bit confused about what was just said or what she was going to do, but it usually comes to her now with a bit of thought...and we can laugh about it now, relieved she won't be getting worse any time soon.

I don't think doctors are immune from the patent since the treatment is a procedure that involves the use of a patented composition of matter (Enbrel). Dr. Tobinick has chosen to teach others…he didn’t have to. Patents are there to encourage people to disclose their inventions. Dr. Tobinick will issue them a license to do the treatment. Beyond that, this treatment is a miraculous breakthrough. Many doctors still don't know about it, and many still think it's a placebo effect. The percentages of effectiveness are way to high for this to be a placebo effect...it's just not scientifically possible. So that leaves one thing...This is real, and some very important parts of my Mom have come back to us. Please see my Mom on youtube: http://youtube.com/user/famc17 Sincerely, Felicia

Enbrel for Alzheimer's

Robert Lee

5/5/2008 9:33:29 AM

It is most unfortunate that the results shown in Dr. Tobinick's report in the Journal of Neuroinflammation in Jan. '08, and the prior 2006 study of 15 patients are lacking any follow up reporting of his continuing treatment of these patients.

Dr. Tobinick has received procedure patents for the entire field of 32 drugs relating to cytokines, 17 methods of drug delivery (all the routes possible) and has patent claims for treatment of 65 diseases. The two small case studies for a single drug published by Dr. Tobinick are the total body of work available to justify his claims to treat 65 diseases with patented methods with licenses for sale.

I believe that the Enbrel treatment for AD has merit, and have had the method duplicated by a qualified neurologist for my wife Linda, 51, who has severe EOAD. The results were significant enough after the first month with 4 injections to have us continue. We have posted Linda Lee's before/after videos on You Tube in the interest of educating people researching this issue: http://www.youtube.com/watch?v=JdSsdxzrjMk.

I hope Dr. Tobinick's unconventional business methods and procedure patents will not stifle research into etanercept and related medications for AD. Doctors are immune from procedure patents, but the threat of litigation can be very intimidating, and is sure to dampen exploration in this area.